Takeda loses sole lead among admired Japanese pharmaceutics companies - by P Reed Maurer

International Alliances Limited (IAL), headed by Japanese drug industry veteran P Reed Maurer, has presented the results of its 11th annual survey of Japan's most admired pharmaceutical companies. This covered 30 companies, 15 of which are Japanese and 15 affiliates of foreign drugmakers. They included:

Japanese   Foreign
Astellas   Abbott   
Daiichi-Sankyo   AstraZeneca
Dainippon Sumitomo  Banyu
Eisai    Bayer Yakuhin
Kissei    Bristol-Myers
Kyorin    Chugai
Kyowa Hakko Kirin  Eli Lilly
Meiji Seika   GlaxoSmithKline
Mitsubishi Tanabe  Janssen Pharma
Mochida Nippon    Boehringer Ingelheim
Nippon Shinyaku   Novartis
Ono    Novo Nordisk
Otsuka    Pfizer
Shionogi   Sanofi-Aventis
Takeda    UCB

Each company was evaluated on eight categories of performance: Quality of Management; Quality of Products; Potential for Growth; New Drug Discovery Potential; Quality of Development; Quality of Medical Representatives (MRs); Profitability in the Future; Overall Opinion. There were three categories of responders: employees of pharma companies, wholesalers, and service providers.  These industry "insidersâ are well positioned to objectively evaluate the eight categories of performance for each company.